Acute Promyelocytic Leukemia Overview

Save information for later
Sign Up

Learn About Acute Promyelocytic Leukemia

View Main Condition: Leukemia

What is the definition of Acute Promyelocytic Leukemia?
Acute promyelocytic leukemia (APL) is an aggressive type of acute myeloid leukemia in which there are too many immature blood-forming cells (promyelocytes) in the blood and bone marrow. This build up of promyelocytes leads to a shortage of normal white and red blood cells and platelets in the body. The signs and symptoms of APL include an increased risk to both bleed and form blood clots. Individuals may also experience excessive tiredness, pain in affected areas, loss of appetite, and weight loss. It is caused by a genetic change that is acquired over a person's lifetime, usually involving a translocation between chromosomes 15 and 17.
What are the alternative names for Acute Promyelocytic Leukemia?
  • Acute promyelocytic leukemia
  • AML M3
  • AML with t(15;17)(q22;q12);(PML/RARalpha) and variants
  • APML
  • Acute myeloblastic leukemia 3
  • Acute myeloblastic leukemia type 3
  • Acute myeloid leukemia with t(15;17)(q22;q12);(PML/RARalpha) and variants
Who are the top Acute Promyelocytic Leukemia Local Doctors?
Elite in Acute Promyelocytic Leukemia
Dr. Martin S. Tallman
Hematology
Elite in Acute Promyelocytic Leukemia
Dr. Martin S. Tallman
Hematology
675 N Saint Clair St, Galter 21-100, 
Chicago, IL 
312-695-0990
Languages Spoken:
English
See accepted insurances

Martin Tallman is a Hematologist in Chicago, Illinois. Dr. Tallman is rated as an Elite provider by MediFind in the treatment of Acute Promyelocytic Leukemia. His top areas of expertise are Acute Promyelocytic Leukemia, Acute Myeloid Leukemia (AML), Hairy Cell Leukemia (HCL), Bone Marrow Transplant, and Bone Marrow Aspiration.

Elite in Acute Promyelocytic Leukemia
Dr. Bayard L. Powell
Oncology | Hematology
Elite in Acute Promyelocytic Leukemia
Dr. Bayard L. Powell
Oncology | Hematology

Wake Forest University Health Sciences

Medical Ctr Blvd, 
Winston Salem, NC 
336-716-2734
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Bayard Powell is an Oncologist and a Hematologist in Winston Salem, North Carolina. Dr. Powell is rated as an Elite provider by MediFind in the treatment of Acute Promyelocytic Leukemia. His top areas of expertise are Acute Myeloid Leukemia (AML), Acute Promyelocytic Leukemia, Leukemia, Acute Lymphoblastic Leukemia (ALL), and Bone Marrow Aspiration. Dr. Powell is currently accepting new patients.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Acute Promyelocytic Leukemia
Dr. Tapan M. Kadia
Hematology | Oncology
Elite in Acute Promyelocytic Leukemia
Dr. Tapan M. Kadia
Hematology | Oncology

MD Anderson

2130 W Holcombe Blvd, Univ Of Tx M D Ande Life, 
Houston, TX 
713-592-5433
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Tapan Kadia is a Hematologist and an Oncologist in Houston, Texas. Dr. Kadia is rated as an Elite provider by MediFind in the treatment of Acute Promyelocytic Leukemia. His top areas of expertise are Acute Myeloid Leukemia (AML), Leukemia, Myelodysplastic Syndrome (MDS), Bone Marrow Aspiration, and Bone Marrow Transplant.

View All Doctors
What are the latest Acute Promyelocytic Leukemia Clinical Trials?
Phase I Trial of TURALIO (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor (TGCT)
Phase I Trial of TURALIO (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor (TGCT)
Who is this study for: Child to adult patients with Recurrent or Refractory Solid Tumors or Acute Leukemia
Enrollment Status: Recruiting
Publish Date: September 08, 2025
Intervention Type: Drug
Study Drug: PLX3397
Study Phase: Phase 1

Background: \- Some people with cancer have solid tumors. Others have refractory leukemia. This may not go away after treatment. Researchers want to see if a drug called TURALIO(R) can shrink tumors or stop them from growing.

Match to trials
Find the right clinical trials for you in under a minute
Get started
Phase II Study of Treatment of Acute Promyelocytic Leukemia (APL) With ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin (GO)
Phase II Study of Treatment of Acute Promyelocytic Leukemia (APL) With ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin (GO)
Who is this study for: Child to adult patients with Acute Promyelocytic Leukemia
Enrollment Status: Recruiting
Publish Date: July 30, 2025
Intervention Type: Drug, Other
Study Drugs: Arsenic Trioxide, Gemtuzumab, Tretinoin
Study Phase: Phase 2

Summary: This phase II trial studies how well tretinoin and arsenic trioxide with or without gemtuzumab ozogamicin works in treating patients with previously untreated acute promyelocytic leukemia. Drugs used in chemotherapy, such as tretinoin and arsenic trioxide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them fro...

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center